Mirati Declaration of Compliance

Mirati Declaration of Compliance Pursuant to California Health and Safety Codes §§ 119400-119402

At Mirati Therapeutics, a Bristol Myers Squibb Company, we are committed to conducting our business with the highest standards of ethics and integrity. This commitment is a foundational element to our organizational success, and adherence to these standards ultimately protects patient welfare and generates and sustains value for Mirati, our employees, and stakeholders. We have developed a Comprehensive Compliance Program (CCP) structured around the seven elements outlined in the April 2003 “Compliance Program Guidance for Pharmaceutical Manufacturers,” published by the United States Department of Health and Human Services, Office of Inspector General (OIG Guidance) that reflects this commitment.

Based on Mirati’s good faith understanding of California Health and Safety Code §§ 119400-119402 (California Act), our CCP is in compliance with California requirements. This includes the following:

  1. Appointing a Chief Compliance Officer;
  2. Maintaining policies that are designed to comply with the Pharmaceutical Research and Manufacturers of America’s “Code on Interactions with Health Care Professionals” (PhRMA Code). Mirati has established an annual dollar amount limit as required by California, of $2,500, which applies to gifts, promotional materials, items, and activities that Mirati may give or otherwise provide to an individual medical or health care professional in accordance with the OIG Guidance and PhRMA Code;
  3. Providing education and training to incorporate the OIG Guidance, PhRMA Code, anti-kickback laws, the federal False Claims Act, and FDA regulations;
  4. Promoting open lines of communications between all employees and the Compliance team;
  5. Conducting auditing and monitoring activities to review for compliance with our policies and identify potential areas of risk;
  6. Appropriately responding to Potential Compliance Violations; and
  7. Taking corrective actions to prevent unlawful or unethical behavior.

California Health and Safety Codes §§ 119400 -119402 require Mirati to “…make its Comprehensive Compliance Program [CCP] . . . available to the public.” For the purpose of satisfying that requirement, the above description provides an overview of Mirati’s CCP as of February 13, 2024.

To the best of our knowledge, Mirati Therapeutics declares that as of February 13, 2024, we are in compliance with all material aspects of the California Act.

Copies of this declaration and the Compliance Program may be obtained by calling this toll-free number, 1-844-647-2841.

Dated: March 1, 2024